Continuous Glucose Monitoring in Insulin-Treated Type 2 Diabetes Mellitus in Sweden: A Scoping Review and Policy Landscape Analysis
Authors' conclusion
The benefits associated with CGM show that an expansion of the Swedish recommendations to cover all insulin-treated people with T2DM is warranted. Persistent regional disparities must be addressed to ensure equitable access to care for people with T2DM in Sweden. The establishment of dedicated funding mechanisms within primary care should be considered to promote more equitable and sustainable access.
Study context
- Population
- People with insulin-treated T2D (intensive insulin or basal insulin only); Swedish and European guidelines
- Comparison
- Continuous glucose monitoring (CGM) vs self-monitoring of blood glucose (SMBG)
- Outcome
- Clinical, patient and economic value of CGM; access in Sweden
Main finding
As reported in the abstract
- CGM associated with improved clinical outcomes vs SMBG, both with intensive insulin and basal insulin only
- Clinical benefits likely translate into fewer long-term diabetes complications and reduced resource utilization and budget impact vs SMBG
- Health economic evaluations: CGM can be considered cost-effective for all insulin-treated individuals in Sweden
- European-wide guidance supports considering CGM for all insulin-treated individuals; access in Sweden limited outside high-risk intensive insulin-treated population
- Regional heterogeneity in access, partly from attribution of budget responsibility to individual primary care units
Original publication
Continuous Glucose Monitoring in Insulin-Treated Type 2 Diabetes Mellitus in Sweden: A Scoping Review and Policy Landscape Analysis. Diabetes Technol Ther. Published 14 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →